Effectiveness of first-line cetuximab in wild-type RAS metastatic colorectal cancer according to tumour BRAF mutation status from the EREBUS cohort.

Magali RouyerEric FrançoisAntonio Sa CunhaAlain MonnereauEmmanuelle BignonJérémy JovéRégis LassalleCécile Droz-PerroteauNicholas MoorePernelle NoizeAnnie Fourrier-RéglatDenis Smith

Published in: British journal of clinical pharmacology (2020)

BRAF mutations were associated with markedly poorer outcomes in initially unresectable RASwt mCRC patients treated by cetuximab in first-line treatment.

Keyphrases

wild type
metastatic colorectal cancer
randomized controlled trial
systematic review
locally advanced
liver metastases
type diabetes
rectal cancer